76 results
SC 14D9
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
Leadership (incorporated by reference to Exhibit 99.2 to the Schedule 14D-9C. filed by MorphoSys with the SEC on February 6, 2024).
(a)(5)(F)
Employee One
SC 14D9
EX-99
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
considered that pursuant to the Business Combination Agreement, Novartis AG acknowledges the outstanding leadership and management skills … leadership and management skills and capabilities as well as deep industry knowledge of the current members of the Management Board. The Bidder. Novartis
SC TO-T
EX-99
MOR
Morphosys AG
11 Apr 24
Third party tender offer statement
6:01am
, in 1982. He held a number of senior leadership positions at Novartis, including Chief Operating Officer and Head of the Vaccines and Diagnostics Division … , professor and senior administrator at leading academic institutions and hospitals. Her distinguished career spans more than 30 years, with leadership
6-K
EX-99.1
MOR
Morphosys AG
20 Mar 24
Current report (foreign)
4:12pm
and generally members of the Global Leadership Group. They identify the risks in their respective areas in close coordination with the central Global … between identified risks. Workshops are held with selected risk agents and the leadership of the departments Financial Planning & Analysis (FP
SC14D9C
EX-99.1
MOR
Morphosys AG
15 Mar 24
Written communication relating to third party tender offer
4:46pm
progress at MorphoSys, resulting in our proposed acquisition by Novartis. We are confident that Novartis’ global footprint and leadership in oncology
SC14D9C
EX-99.1
d3bnrql0
14 Mar 24
Written communication relating to third party tender offer
4:52pm
SC14D9C
EX-99.3
gsxk8o9s
13 Mar 24
Written communication relating to third party tender offer
5:22pm
SC14D9C
EX-99.4
ehl3iu8u b3
13 Mar 24
Written communication relating to third party tender offer
5:22pm
6-K
EX-99.1
4ykhfgqhm7q4s9a
13 Mar 24
Non-Financial Group Report 2023
4:12pm
6-K
EX-99.1
8b0ci 3t238d8
13 Mar 24
Current report (foreign)
4:08pm
SC14D9C
EX-99.1
dl7juc q3
12 Feb 24
Written communication relating to third party tender offer
5:03pm
6-K
EX-99.3
6y9ag03z
7 Feb 24
MorphoSys Enters into Business Combination Agreement to be
6:57am
SC14D9C
EX-99.9
n7nljxbxx o7pz
6 Feb 24
Written communication relating to third party tender offer
4:58pm
SC14D9C
EX-99.2
311jcqkm
6 Feb 24
Written communication relating to third party tender offer
4:58pm
SC14D9C
EX-99.1
k49cd sgh0iao2
6 Feb 24
Written communication relating to third party tender offer
4:58pm
SC14D9C
23spesa3xg8ey
6 Feb 24
Written communication relating to third party tender offer
4:58pm
SC14D9C
EX-99.3
56gu4by1qm2js aa
5 Feb 24
Written communication relating to third party tender offer
5:11pm
6-K
EX-99.1
hm76zm19jgobs1t
16 Nov 22
Third Quarter Interim Statement January – September
4:14pm
6-K
EX-99.1
lsgpwe ddrbxo
31 Aug 22
MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
4:08pm